Prostate cancer (PC) is among the most common cancer diagnoses in men worldwide and the fifth leading cause of cancer-related deaths. Approximately 1.5 million new cases of PC were reported worldwide in 2022 with near...Prostate cancer (PC) is among the most common cancer diagnoses in men worldwide and the fifth leading cause of cancer-related deaths. Approximately 1.5 million new cases of PC were reported worldwide in 2022 with nearly 400,000 associated deaths1. Notably, the incidence of PC in China has increased substantially compared to the global average2.展开更多
Biliary tract cancer(BTC)is a group of rare malignancies that affect the gallbladder and bile ducts.Although rare,BTC is becoming a significant public health burden in China,particularly among males and older individu...Biliary tract cancer(BTC)is a group of rare malignancies that affect the gallbladder and bile ducts.Although rare,BTC is becoming a significant public health burden in China,particularly among males and older individuals.The increasing trends in BTC incidence and mortality in China are influenced by various demographic,environmental,and lifestyle factors.In this review,we examine available epidemiological data on the incidence,mortality,prognosis,and trends of different BTC subtypes in China.We also discuss the challenges and opportunities for improving the prevention,diagnosis,and management of BTC in China,and identify areas for further research and intervention.The article aims to provide a better understanding of the epidemiological features of BTC in China and to inform public health strategies and clinical practice.展开更多
Objective:Esophageal cancer(EC)ranks eighth among cancers in cancer-related deaths globally,and~44%of new cases occur in China.We sought to describe the clinical characteristics and treatment landscape of EC in China ...Objective:Esophageal cancer(EC)ranks eighth among cancers in cancer-related deaths globally,and~44%of new cases occur in China.We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020.Methods:CHANNEL was a large,retrospective study using patient-level data from 14 hospitals/cancer centers across China,including adults initiating therapy for newly diagnosed EC(January to December 2018).Demographics,clinicopathologic characteristics,and treatment patterns over 6 months were descriptively summarized.Results:Of 3,493 patients,75.7%were men,the mean age was 64.1 years,and 75.0%had no family history of cancer.Most(92.8%)had squamous cell carcinoma,with a primary lesion in the middle esophagus(56.4%).Among patients with resectable EC,92.9%received initial surgery,and 7.1%received neoadjuvant therapy,primarily chemotherapy(85.5%platinum-taxane).Among patients with unresectable early or locally advanced EC,50.8%and 49.2%received palliative and radical therapy,respectively,as the initial treatment,primarily chemotherapy(66.5%platinum-taxane)and chemoradiotherapy(50.8%platinum-taxane),respectively.Adjuvant therapy was administered to 22.9%of patients undergoing initial surgery,and 2.4%receiving neoadjuvant therapy and surgery.Among patients with advanced EC,84.6%received systemic therapy as an initial treatment,primarily chemotherapy(61.5%platinum-taxane).Conclusions:Before the approval of immunotherapy in China,most patients with resectable early or locally advanced EC underwent radical surgery without preoperative treatment,whereas most patients with advanced EC received platinum-taxane chemotherapy.These findings highlight the need for novel EC treatments before immunotherapy was introduced,and provide a baseline for evaluating the benefits of immunotherapy,now that this treatment is widely used in this setting.展开更多
To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a rare but serious condition characterized by obstruction of the pulmonary arteries due to thromboembolic events and subsequent vascular remodeling,...To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a rare but serious condition characterized by obstruction of the pulmonary arteries due to thromboembolic events and subsequent vascular remodeling,which leads to pulmonary hypertension(PH).Classified as Group 4 in the 2022 PH guidelines by the European Society of Cardiology and the European Respiratory Society,CTEPH poses significant risks,including progressive PH,right ventricular dysfunction,and mortality if left untreated.Despite established diagnostic and treatment guidelines,the exact national prevalence of CTEPH remains largely unknown due to the absence of organized registries,with estimates ranging from 3 to 30 cases per million people.Although CTEPH is commonly thought to follow acute pulmonary embolism(PE),epidemiological data reveal a discrepancy;studies suggest that only 0.1%to 3.8%of PE patients may develop CTEPH.展开更多
To the Editor:Endometrial cancer(EC)ranks as the second most common gynecologic malignancy in China,with rising incidence rates.[1,2]In China,the 5-year survival rate for EC patients has improved from 55.1%in 2003–20...To the Editor:Endometrial cancer(EC)ranks as the second most common gynecologic malignancy in China,with rising incidence rates.[1,2]In China,the 5-year survival rate for EC patients has improved from 55.1%in 2003–2005 to 72.8%in 2012–2015.However,due to sociodemographic,clinicopathological,and treatment-related factors,this remains lower than the 81%in the United States.[3,4]EC is a complex disease with multiple risk factors,distinct histological subtypes,and a variety of available therapeutic options.However,we know very little about the real-world characteristics and treatment patterns of EC in China.[5]Therefore,this large-scale,multicenter study aimed to investigate the demographic,histopathological,and molecular features of newly diagnosed EC patients in China,as well as to provide insights into current treatment patterns.展开更多
Chemotherapy-induced nausea and vomiting(CINV)is common in patients receiving moderately or highly emetogenic chemotherapy and is caused by the activation of peripheral and central nervous system pathways,with the neu...Chemotherapy-induced nausea and vomiting(CINV)is common in patients receiving moderately or highly emetogenic chemotherapy and is caused by the activation of peripheral and central nervous system pathways,with the neurokinin-1 receptor playing a central role in delayed CINV.Neurokinin-1 receptor antagonists(NK1RAs)in combination with other antiemetic agents are recommended in international and Chinese guidelines for the prevention of acute and delayed CINV.Therefore,a summary of current data for NK1RAs would be of great clinical utility.This article summarizes the available clinical and real-world data on the use of NK1RAs in CINV prophylaxis,with a focus on evidence from China,where three NK1RAs,aprepitant,fosaprepitant and netupitant,are currently approved.NK1RAs have demonstrated efficacy and favorable safety in the prevention of acute and delayed CINV.Further research is required to determine the optimal use of these drugs and to identify strategies for CINV management in specific patient populations.展开更多
Biliary tract cancer(BTC)is a rare group of malignancies that develop from the epithelial lining of the biliary tree and have a poor prognosis.Although chemotherapy is the standard of care for patients with advanced B...Biliary tract cancer(BTC)is a rare group of malignancies that develop from the epithelial lining of the biliary tree and have a poor prognosis.Although chemotherapy is the standard of care for patients with advanced BTC in China,its clinical benefits are moderate.In recent years,the approval of targeted therapies and immunotherapies has provided new avenues for the management of advanced BTC.Nonetheless,the increasing number of personalized medicine approaches has created a challenge for clinicians choosing individualized treatment strategies based on tumor characteristics.In this article,we discuss recent progress in implementing precision medicine approaches for advanced BTC in China and examine genomic profiling studies in Chinese patients with advanced BTC.We also discuss the challenges and opportunities of using precision medicine approaches,as well as the importance of considering population-specific factors and tailoring treatment approaches to improve outcomes for patients with BTC.In addition to providing a comprehensive overview of current and emerging precision medicine approaches for the management of advanced BTC in China,this review article will support clinicians outside of China by serving as a reference regarding the role of patient-and population-specific factors in clinical decision-making for patients with this rare malignancy.展开更多
文摘Prostate cancer (PC) is among the most common cancer diagnoses in men worldwide and the fifth leading cause of cancer-related deaths. Approximately 1.5 million new cases of PC were reported worldwide in 2022 with nearly 400,000 associated deaths1. Notably, the incidence of PC in China has increased substantially compared to the global average2.
文摘Biliary tract cancer(BTC)is a group of rare malignancies that affect the gallbladder and bile ducts.Although rare,BTC is becoming a significant public health burden in China,particularly among males and older individuals.The increasing trends in BTC incidence and mortality in China are influenced by various demographic,environmental,and lifestyle factors.In this review,we examine available epidemiological data on the incidence,mortality,prognosis,and trends of different BTC subtypes in China.We also discuss the challenges and opportunities for improving the prevention,diagnosis,and management of BTC in China,and identify areas for further research and intervention.The article aims to provide a better understanding of the epidemiological features of BTC in China and to inform public health strategies and clinical practice.
文摘Objective:Esophageal cancer(EC)ranks eighth among cancers in cancer-related deaths globally,and~44%of new cases occur in China.We sought to describe the clinical characteristics and treatment landscape of EC in China before the approval of immunotherapy in 2020.Methods:CHANNEL was a large,retrospective study using patient-level data from 14 hospitals/cancer centers across China,including adults initiating therapy for newly diagnosed EC(January to December 2018).Demographics,clinicopathologic characteristics,and treatment patterns over 6 months were descriptively summarized.Results:Of 3,493 patients,75.7%were men,the mean age was 64.1 years,and 75.0%had no family history of cancer.Most(92.8%)had squamous cell carcinoma,with a primary lesion in the middle esophagus(56.4%).Among patients with resectable EC,92.9%received initial surgery,and 7.1%received neoadjuvant therapy,primarily chemotherapy(85.5%platinum-taxane).Among patients with unresectable early or locally advanced EC,50.8%and 49.2%received palliative and radical therapy,respectively,as the initial treatment,primarily chemotherapy(66.5%platinum-taxane)and chemoradiotherapy(50.8%platinum-taxane),respectively.Adjuvant therapy was administered to 22.9%of patients undergoing initial surgery,and 2.4%receiving neoadjuvant therapy and surgery.Among patients with advanced EC,84.6%received systemic therapy as an initial treatment,primarily chemotherapy(61.5%platinum-taxane).Conclusions:Before the approval of immunotherapy in China,most patients with resectable early or locally advanced EC underwent radical surgery without preoperative treatment,whereas most patients with advanced EC received platinum-taxane chemotherapy.These findings highlight the need for novel EC treatments before immunotherapy was introduced,and provide a baseline for evaluating the benefits of immunotherapy,now that this treatment is widely used in this setting.
基金supported by the National Key Research and Development Program of China(No.2023YFC2507200)Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)(No.2021-I2M-1-049)+1 种基金National High Level Hospital Clinical Research Funding(No.2022-NHLHCRF-LX-01-0203)National Natural Science Foundation of China(Nos.82241029,and 81970058).
文摘To the Editor:Chronic thromboembolic pulmonary hypertension(CTEPH)is a rare but serious condition characterized by obstruction of the pulmonary arteries due to thromboembolic events and subsequent vascular remodeling,which leads to pulmonary hypertension(PH).Classified as Group 4 in the 2022 PH guidelines by the European Society of Cardiology and the European Respiratory Society,CTEPH poses significant risks,including progressive PH,right ventricular dysfunction,and mortality if left untreated.Despite established diagnostic and treatment guidelines,the exact national prevalence of CTEPH remains largely unknown due to the absence of organized registries,with estimates ranging from 3 to 30 cases per million people.Although CTEPH is commonly thought to follow acute pulmonary embolism(PE),epidemiological data reveal a discrepancy;studies suggest that only 0.1%to 3.8%of PE patients may develop CTEPH.
文摘To the Editor:Endometrial cancer(EC)ranks as the second most common gynecologic malignancy in China,with rising incidence rates.[1,2]In China,the 5-year survival rate for EC patients has improved from 55.1%in 2003–2005 to 72.8%in 2012–2015.However,due to sociodemographic,clinicopathological,and treatment-related factors,this remains lower than the 81%in the United States.[3,4]EC is a complex disease with multiple risk factors,distinct histological subtypes,and a variety of available therapeutic options.However,we know very little about the real-world characteristics and treatment patterns of EC in China.[5]Therefore,this large-scale,multicenter study aimed to investigate the demographic,histopathological,and molecular features of newly diagnosed EC patients in China,as well as to provide insights into current treatment patterns.
基金provided technical help and editorial assistance for this manuscriptsupport for this manuscript was also provided by Dr.Sharon Gladwin(Rude Health Consulting Limited)and funded by MSD Chinafunded by MSD China.
文摘Chemotherapy-induced nausea and vomiting(CINV)is common in patients receiving moderately or highly emetogenic chemotherapy and is caused by the activation of peripheral and central nervous system pathways,with the neurokinin-1 receptor playing a central role in delayed CINV.Neurokinin-1 receptor antagonists(NK1RAs)in combination with other antiemetic agents are recommended in international and Chinese guidelines for the prevention of acute and delayed CINV.Therefore,a summary of current data for NK1RAs would be of great clinical utility.This article summarizes the available clinical and real-world data on the use of NK1RAs in CINV prophylaxis,with a focus on evidence from China,where three NK1RAs,aprepitant,fosaprepitant and netupitant,are currently approved.NK1RAs have demonstrated efficacy and favorable safety in the prevention of acute and delayed CINV.Further research is required to determine the optimal use of these drugs and to identify strategies for CINV management in specific patient populations.
基金funded by MSD China.Editorial support for this manuscript was provided by Dr.Jake Burrell(Rude Health Consulting Limited)Dr.Christos Evangelou(on behalf of Rude Health Consulting Limited)and this support was funded by MSD China.
文摘Biliary tract cancer(BTC)is a rare group of malignancies that develop from the epithelial lining of the biliary tree and have a poor prognosis.Although chemotherapy is the standard of care for patients with advanced BTC in China,its clinical benefits are moderate.In recent years,the approval of targeted therapies and immunotherapies has provided new avenues for the management of advanced BTC.Nonetheless,the increasing number of personalized medicine approaches has created a challenge for clinicians choosing individualized treatment strategies based on tumor characteristics.In this article,we discuss recent progress in implementing precision medicine approaches for advanced BTC in China and examine genomic profiling studies in Chinese patients with advanced BTC.We also discuss the challenges and opportunities of using precision medicine approaches,as well as the importance of considering population-specific factors and tailoring treatment approaches to improve outcomes for patients with BTC.In addition to providing a comprehensive overview of current and emerging precision medicine approaches for the management of advanced BTC in China,this review article will support clinicians outside of China by serving as a reference regarding the role of patient-and population-specific factors in clinical decision-making for patients with this rare malignancy.
